IL2
Interleukin-2
Also known as: IL-2, IL2_HUMAN, TCGF
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P60568
- Gene
- IL2
- Ensembl
- ENSG00000109471
- Chromosome
- 4
- Canonical length
- 153 aa
- Protein class
- Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene is a member of the interleukin 2 (IL2) cytokine subfamily which includes IL4, IL7, IL9, IL15, IL21, erythropoietin, and thrombopoietin. The protein encoded by this gene is a secreted cytokine produced by activated CD4+ and CD8+ T lymphocytes, that is important for the proliferation of T and B lymphocytes. The receptor of this cytokine (IL2R) is a heterotrimeric protein complex whose gamma chain is also shared by IL4 and IL7. The expression of this gene in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling the precise expression of a single gene. The targeted disruption of a similar gene in mice leads to ulcerative colitis-like disease, which suggests an essential role of this gene in the immune response to antigenic stimuli. [provided by RefSeq, Sep 2020]
Canonical amino-acid sequenceUniProt
153 residues, UniProt reviewed canonical sequence.
>P60568|IL2
1 MYRMQLLSCI ALSLALVTNS APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNPKLTRML
61 TFKFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE
121 TTFMCEYADE TATIVEFLNR WITFCQSIIS TLTLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 0.3 nTPM
Expression across tissuesHPA
Tissue
- rectum: 0.3 nTPM
- small intestine: 0.3 nTPM
- tonsil: 0.3 nTPM
- lymph node: 0.2 nTPM
- thymus: 0.2 nTPM
- adipose tissue: 0.1 nTPM
Single-cell type
- t-cells: 18 nCPM
- innate lymphoid cells: 12 nCPM
- nk-cells: 2 nCPM
- parietal cells: 1.8 nCPM
- endometrial luminal cells: 1.3 nCPM
- endometrial glandular cells: 0.5 nCPM
Immune cell
- memory CD4 T-cell: 0.2 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IL2.
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 3 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
Disease | AutoantibodyPubMed
Conditions in which antibodies against IL2 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for IL2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
27 publications
- Autoimmunity is a hallmark of post-COVID syndrome.
2022 · J Transl Med · RCR 10.9 · 129 citations - Production of interleukin 2 (IL 2) by salivary gland lymphocytes in Sjögren's syndrome. Detection of reactive cells by using antibody directed to synthetic peptides of IL 2.
1985 · J Immunol · RCR 2.4 · 84 citations - Proliferating cell nuclear antigen (PCNA)/cyclin in activated human T lymphocytes.
1987 · J Immunol · RCR 2.1 · 88 citations - Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus.
1993 · J Immunol · RCR 2.1 · 98 citations - Anti-cytokine autoantibodies are ubiquitous in healthy individuals.
2007 · FEBS Lett · RCR 2 · 83 citations
Show 20 more of 27 total
- Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody.
1988 · J Immunol · RCR 1.8 · 74 citations - Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody.
1986 · J Immunol · RCR 1.7 · 71 citations - Individuals infected with HIV possess antibodies against IL-2.
1988 · Immunology · RCR 1.7 · 66 citations - Loss of immune tolerance to IL-2 in type 1 diabetes.
2016 · Nat Commun · RCR 1 · 35 citations - Induction of severe granulomatous experimental autoimmune thyroiditis in mice by effector cells activated in the presence of anti-interleukin 2 receptor antibody.
1991 · J Exp Med · RCR 0.9 · 40 citations - The detection and biological activity of human antibodies to IL-2 in normal donors.
1993 · Scand J Immunol · RCR 0.9 · 32 citations - Combination Therapy Using IL-2/IL-2 Monoclonal Antibody Complexes, Rapamycin, and Islet Autoantigen Peptides Increases Regulatory T Cell Frequency and Protects against Spontaneous and Induced Type 1 Diabetes in Nonobese Diabetic Mice.
2015 · J Immunol · RCR 0.9 · 32 citations - Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys.
2001 · Clin Exp Immunol · RCR 0.8 · 37 citations - Toward more selective therapies to block undesired immune responses.
1989 · Kidney Int · RCR 0.8 · 24 citations - Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies.
2009 · Clin Exp Immunol · RCR 0.7 · 31 citations - High recombinant interleukin-2 sensitivity of peripheral blood lymphocytes from patients with myasthenia gravis: correlations with clinical parameters.
1989 · J Autoimmun · RCR 0.7 · 25 citations - Impact of GAD65 and IA2 autoantibodies on islet allograft survival.
2023 · Front Clin Diabetes Healthc · RCR 0.4 · 3 citations - Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin.
2007 · Clin Exp Immunol · RCR 0.3 · 13 citations - Cutting edge: Enhanced IL-2 signaling can convert self-specific T cell response from tolerance to autoimmunity.
2008 · J Immunol · RCR 0.3 · 21 citations - Cytokine/Antibody complexes: an emerging class of immunostimulants.
2009 · Curr Pharm Des · RCR 0.3 · 16 citations - Clinical Relevance of Autoantibodies against Interleukin-2 in Patients with Systemic Lupus Erythematosus.
2018 · Chin Med J (Engl) · RCR 0.3 · 6 citations - IL-2 antibody production in lupus mice.
1989 · Cell Immunol · RCR 0.2 · 10 citations - IL-2 antibodies in type 1 diabetes and during IL-2 therapy.
2018 · Diabetologia · RCR 0.2 · 5 citations - Interleukin-2 mastering regulation in cancer and autoimmunity.
2007 · Ann N Y Acad Sci · RCR 0.2 · 8 citations - Antibodies to interleukin 2 in sera of autoimmune-prone mice.
1990 · Scand J Rheumatol · RCR 0.1 · 2 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.81
- gnomAD pLI
- 0.48
- gnomAD missense Z
- 1.43
- DepMap mean gene effect
- 0.1
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- activated T cell proliferation
- adaptive immune response
- cell adhesion
- cell surface receptor signaling pathway via STAT
- cell-cell signaling
- extrinsic apoptotic signaling pathway in absence of ligand
- immune response
- interleukin-2-mediated signaling pathway
- leukocyte activation involved in immune response
- natural killer cell activation
- negative regulation of apoptotic process
- negative regulation of B cell apoptotic process
- negative regulation of inflammatory response
- negative regulation of lymphocyte proliferation
- negative regulation of T-helper 17 cell differentiation
- phospholipase C-activating G protein-coupled receptor signaling pathway
- positive regulation of activated T cell proliferation
- positive regulation of B cell proliferation
- positive regulation of cell growth
- positive regulation of cell population proliferation
- positive regulation of cytosolic calcium ion concentration
- positive regulation of dendritic spine development
- positive regulation of immunoglobulin production
- positive regulation of inflammatory response
- positive regulation of interleukin-17 production
- positive regulation of isotype switching to IgG isotypes
- positive regulation of plasma cell differentiation
- positive regulation of regulatory T cell differentiation
- positive regulation of tissue remodeling
- positive regulation of transcription by RNA polymerase II
- positive regulation of type II interferon production
- regulation of CD4-positive, alpha-beta T cell proliferation
- regulation of T cell homeostatic proliferation
- response to ethanol
- response to tacrolimus
- T cell differentiation
- transcription by RNA polymerase II
Molecular functions
- carbohydrate binding
- cytokine activity
- glycosphingolipid binding
- growth factor activity
- interleukin-2 receptor binding
- kinase activator activity
- kappa-type opioid receptor binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Four-helical cytokine-like, core
- Interleukin-2
- Interleukin-2, conserved site
- Interleukin 2
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IL2 as an antibody target. Whether an autoantibody or antibody against IL2 could matter depends on whether native IL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IL2 is annotated as secreted, so native IL2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label IL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...